Annual report pursuant to Section 13 and 15(d)

STATEMENTS OF STOCKHOLDERS' EQUITY

v3.21.1
STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Preferred Class A [Member]
Class A Common Shares [Member]
Common Shares [Member]
Common Stock Issuable
Additional Paid-in Capital
Accumulated Deficit
Total
Balances at Dec. 31, 2018     $ 3 $ 2,085 $ 113,378 $ (79,070) $ 36,396
Balances (in shares) at Dec. 31, 2018 250,000 1,000,000 26,610,183        
Common stock issuable - Founders Agreement       4,923     4,923
Issuance of common shares - Founders Agreement       (2,085) 2,085    
Issuance of common shares - Founders Agreement (in shares)     709,314        
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech         375   375
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech (in shares)     108,069        
Issuance of warrants - Horizon Notes         888   888
Conversion of Class A common shares to common shares (in shares)   (154,615) 154,615        
Issuance of common shares, net of offering costs - At-the-Market Offering         21,972   21,972
Issuance of common shares, net of offering costs - At-the-Market Offering (in Shares)     3,506,222        
Issuance of common shares - Equity fee on At-the-Market Offering         495   495
Issuance of common shares - Equity fee on At-the-Market Offering (in shares)     87,656        
Issuance of common shares, net of offering costs- Public Offering     $ 1   29,536   29,537
Issuance of common shares, net of offering costs- Public Offering (in shares)     7,906,250        
Issuance of common shares - Equity fee on Public Offering         791   791
Issuance of common shares - Equity fee on Public Offering (in shares)     197,656        
Stock-based compensation expenses         2,664   2,664
Stock-based compensation expenses (in shares)     30,341        
Exercise of warrants (in shares)     93,213        
Net loss           (46,389) (46,389)
Balances at Dec. 31, 2019     $ 4 4,923 172,184 (125,459) 51,652
Balances (in shares) at Dec. 31, 2019 250,000 845,385 39,403,519        
Common stock issuable - Founders Agreement       7,577     7,577
Issuance of common shares - Founders Agreement       (4,923) 4,923    
Issuance of common shares - Founders Agreement (in shares)     1,206,667        
Issuance of common shares, net of offering costs - At-the-Market Offering     $ 2   58,595   58,597
Issuance of common shares, net of offering costs - At-the-Market Offering (in Shares)     17,579,097        
Issuance of common shares - Equity fee on At-the-Market Offering       362 1,152   1,514
Issuance of common shares - Equity fee on At-the-Market Offering (in shares)     342,773        
Issuance of common shares, net of offering costs- Public Offering     $ 1   34,841   34,842
Issuance of common shares, net of offering costs- Public Offering (in shares)     11,455,604        
Issuance of common shares - Equity fee on Public Offering         932   932
Issuance of common shares - Equity fee on Public Offering (in shares)     286,390        
Issuance of common shares under ESPP         349   $ 349
Issuance of common shares under ESPP (in shares)     140,856       140,856
Stock-based compensation expenses         2,987   $ 2,987
Stock-based compensation expenses (in shares)     502,788        
Exercise of warrants (in shares)     2,999        
Net loss           (60,015) (60,015)
Balances at Dec. 31, 2020     $ 7 $ 7,939 $ 275,963 $ (185,474) $ 98,435
Balances (in shares) at Dec. 31, 2020 250,000 845,385 70,920,693